Health Trials

Allogeneic Hematopoietic Cell Transplant

2

Review clinical trials related to Allogeneic Hematopoietic Cell Transplant. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

Participants needed: 115
Trial details
Phase: Phase 3Biological sex: AllType: InterventionalSponsor: Pierre Fabre MedicamentUpdated: May 22, 2026Locations: 71
Eligibility criteria

Prior SOT of kidney, liver, heart, lung, pancreas, small bowel, or any combinati... [+12]

Currently active Burkitt, T-cell, NK/T-cell lymphoma/LPD, Hodgkin, plasmablastic... [+11]

Read more
Status: Recruiting

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation from alternative donor.

Participants needed: 316
Trial details
Phase: Phase 3Age: 18-55Biological sex: AllType: InterventionalSponsor: Shanghai Jiao Tong University School of MedicineUpdated: Mar 17, 2026Locations: 1
Eligibility criteria

patients undergo allo-HSCT with matched unrelated donor or haplo-identical donor... [+4]

Pregnancies [+3]

Read more